Riders · The University of Texas Rio Grande Valley School of Medicine · Article III: Agencies of Education
Cancer Center
Rider 7 in the 2026-27 Act, page III-236
Through the session
- 2024-25 Act Not in this version
- Introduced (Senate) Not in this version
- Introduced (House) Not in this version
- Senate substitute Not in this version
- House substitute New rider 7
- House passed Unchanged rider 7
- Conference Amended rider 7
- 2026-27 Act Unchanged rider 7
Pick any two steps to compare their wording.
What changed in the text
House passed → Conference: 5 passages changed.
Removed words are struck through; added words are underlined. Sources: House passed · Conference.
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | Not in this version | |||
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | Not in this version | |||
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | Not in this version | |||
| Senate substituteCommittee Substitute for Senate Bill 1 | Not in this version | |||
| House substituteHouse Committee Substitute for Senate Bill 1 | 7 | New | New | Page III-199 |
| House passedSenate Bill 1 as passed the second house | 7 | Unchanged | New | Page III-199 |
| ConferenceConference Committee Report for Senate Bill 1 | 7 | Amended | New | Page III-212 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 7 | Unchanged | New | Page III-236 |
Full text of each wording
Conference, 2026-27 Act
Source, page III-236Cancer Center. Out of funds appropriated above in Strategy D.1.2, Cancer Center/Cancer Research, $2,500,000 from the General Revenue Fund in fiscal year 2026 and $2,500,000 from the General Revenue Fund in fiscal year 2027 shall be used to support clinical operations and research at the institution’s Cancer and Surgery Center. Any unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning on September 1, 2026.
House substitute, House passed
Source, page III-199Cancer Immunology Center. Out of funds appropriated above in Strategy D.1.2, Cancer Center/Cancer Research, $2,500,000 from the General Revenue Fund in fiscal year 2026 and $2,500,000 from the General Revenue Fund in fiscal year 2027 shall be used for the Cancer Immunology Center. All unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning on September 1, 2026.